首页 / 院系成果 / 成果详情页

Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study 期刊论文

编号：

0B1525E6BDC27B04D3E0DE796F214101
作者：

Gui, Lin#^[1]Liu, Haifeng^[2];Wang, Huaqing^[3];Cao, Junning^[4];Li, Yufu^[5];Yu, Yong^[6];Gao, Yuhuan^[7];Li, Zhenling(李振玲)^[8]Shen, Jianzhen^[9];Zhang, Lei^[10];Zhang, Qingyuan^[11];Pan, Hongming^[12];Zheng, Meifang^[13];Ke, Xiaoyan^[14];He, Hesheng^[15];Guo, Shuangshuang^[16];Wang, Yihao^[17];Xu, Xiaohong^[18];Zou, Liqun^[19];Wu, Wentao^[20];Shi, Yuankai*^[1]
语种：

英文
期刊：

SIGNAL TRANSDUCTION AND TARGETED THERAPY ISSN：2095-9907 2026 年 11 卷 1 期 ; APR 27
收录：
摘要：

This phase 2, single-arm, multi-center study (NCT03934567) evaluates the efficacy and safety of abexinostat, a histone deacetylase inhibitor, in patients with relapsed or refractory (r/r) follicular lymphoma (FL). Eligible participants had previously received a minimum of two systemic treatment lines, such as cytotoxic agents and/or anti-CD20 monoclonal antibodies. Participants received abexinostat 80 mg oral twice daily on a schedule of seven days on and seven days off, within 28-day cycles, continuing until unacceptable toxicity or disease progression occurred. The primary endpoint was objective response rate (ORR), evaluated by an independent review committee (IRC). Secondary endpoints comprised duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Between May 2, 2019, and November 19, 2023, 90 patients were enrolled. As of October 08, 2024, with a median follow-up of 30.55 months (95% confidence interval [CI] 23.72-33.64), 17.8% (16/90) of patients were still on study treatment. The ORR was 69.5% (57/82, 95% CI 58.4-79.2), with a complete response rate of 14.6% (12/82). The DCR was 91.5% (75/82, 95% CI 83.2-96.5). Tumor size reduced in 89% (73/82) of patients. The median DoR was 13.96 months (95% CI 9.20-not reached [NR]) and the median PFS was 13.80 months (95% CI 9.69-30.26). The median OS was 47.18 months (95% CI 45.70-NR). The most common treatment-emergent adverse events were thrombocytopenia (77/90, 85.6%), neutropenia (53/90, 58.9%), and leukopenia (47/90, 52.2%). The results of this study demonstrated that abexinostat had promising efficacy and manageable safety profile, supporting abexinostat as a new treatment option for the third-line or later-line treatment of r/r FL.
推荐引用方式
GB/T 7714：

Gui Lin,Liu Haifeng,Wang Huaqing, et al. Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study [J].SIGNAL TRANSDUCTION AND TARGETED THERAPY,2026,11(1).
APA：

Gui Lin,Liu Haifeng,Wang Huaqing,Cao Junning,&Shi Yuankai.(2026).Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study .SIGNAL TRANSDUCTION AND TARGETED THERAPY,11(1).
MLA：

Gui Lin, et al. "Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study" .SIGNAL TRANSDUCTION AND TARGETED THERAPY 11,1(2026).
入库时间：

2026/5/6 8:56:56
更新时间：

2026/5/6 8:56:56
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：5  下载次数：0

分享到：

浏览次数：5

下载次数：0

打印次数：0